1. Home
  2. RSVR vs UPB Comparison

RSVR vs UPB Comparison

Compare RSVR & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RSVR
  • UPB
  • Stock Information
  • Founded
  • RSVR 2007
  • UPB 2021
  • Country
  • RSVR United States
  • UPB United States
  • Employees
  • RSVR N/A
  • UPB N/A
  • Industry
  • RSVR Movies/Entertainment
  • UPB
  • Sector
  • RSVR Consumer Discretionary
  • UPB
  • Exchange
  • RSVR Nasdaq
  • UPB NYSE
  • Market Cap
  • RSVR 553.7M
  • UPB 622.8M
  • IPO Year
  • RSVR N/A
  • UPB 2024
  • Fundamental
  • Price
  • RSVR $7.91
  • UPB $11.00
  • Analyst Decision
  • RSVR Strong Buy
  • UPB Strong Buy
  • Analyst Count
  • RSVR 1
  • UPB 4
  • Target Price
  • RSVR $12.50
  • UPB $56.50
  • AVG Volume (30 Days)
  • RSVR 38.9K
  • UPB 442.0K
  • Earning Date
  • RSVR 02-05-2025
  • UPB 02-14-2025
  • Dividend Yield
  • RSVR N/A
  • UPB N/A
  • EPS Growth
  • RSVR N/A
  • UPB N/A
  • EPS
  • RSVR N/A
  • UPB N/A
  • Revenue
  • RSVR $149,606,040.00
  • UPB $2,207,000.00
  • Revenue This Year
  • RSVR $7.18
  • UPB N/A
  • Revenue Next Year
  • RSVR $7.33
  • UPB N/A
  • P/E Ratio
  • RSVR N/A
  • UPB N/A
  • Revenue Growth
  • RSVR 10.84
  • UPB 82.10
  • 52 Week Low
  • RSVR $5.95
  • UPB $10.36
  • 52 Week High
  • RSVR $9.83
  • UPB $29.46
  • Technical
  • Relative Strength Index (RSI)
  • RSVR 37.64
  • UPB N/A
  • Support Level
  • RSVR $7.62
  • UPB N/A
  • Resistance Level
  • RSVR $8.00
  • UPB N/A
  • Average True Range (ATR)
  • RSVR 0.32
  • UPB 0.00
  • MACD
  • RSVR -0.08
  • UPB 0.00
  • Stochastic Oscillator
  • RSVR 20.50
  • UPB 0.00

About RSVR Reservoir Media Inc.

Reservoir Media Inc is an independent music company. The company's segment includes Music Publishing; Recorded Music and others. It generates the maximum of its revenue from the Music Publishing segment.

About UPB UPSTREAM BIO INC

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.

Share on Social Networks: